keyword
https://read.qxmd.com/read/38652876/reader-response-pediatric-and-adult-brain-death-death-by-neurologic-criteria-consensus-guideline-report-of-the-aan-guidelines-subcommittee-aap-cns-and-sccm
#1
JOURNAL ARTICLE
https://read.qxmd.com/read/38652495/evaluation-of-noise-levels-and-noise-sources-in-an-irish-neonatal-intensive-care-unit
#2
JOURNAL ARTICLE
Margaret McCallig, Vikram Pakrashi, Carmel Durkin
OBJECTIVES: This study: (i) quantified the typical noise levels in an Irish neonatal intensive care unit (NICU) and compared the values to recommendations by the American Academy of Paediatrics (AAP) and the European Standards for Care for Newborn Health (EFCNI) and to occupational exposure limit value and exposure action values; and (ii) qualified the perception of noise levels and the sources of noise across the various stakeholders within a typical NICU. METHODS: A noise survey was conducted in an Irish NICU...
April 23, 2024: Annals of Work Exposures and Health
https://read.qxmd.com/read/38649550/third-generation-solid-dispersion-based-formulation-of-novel-anti-tubercular-agent-exhibited-improvement%C3%A2-in-solubility-dissolution-and-biological-activity
#3
JOURNAL ARTICLE
Gourav Paudwal, Rigzin Dolkar, Summaya Perveen, Rashmi Sharma, Parvinder Pal Singh, Prem N Gupta
The long treatment period and development of drug resistance in tuberculosis (TB) necessitates the discovery of new anti-tubercular agents. The drug discovery program of the institute leads to the development of an anti-tubercular lead (IIIM-019), which is an analogue of nitrodihydroimidazooxazole and exhibited promising anti-tubercular action. However, IIIM-019 displays poor aqueous solubility (1.2 µg/mL), which demands suitable dosage form for its efficient oral administration. In the present study, third generation solid dispersion-based formulation was developed to increase the solubility and dissolution of IIIM-019...
April 22, 2024: AAPS Journal
https://read.qxmd.com/read/38649513/qbd-based-formulation-development-and-optimisation-of-ozenoxacin-topical-nano-emulgel-and-efficacy-evaluation-using-impetigo-mice-model
#4
JOURNAL ARTICLE
Amarnath Reddy Ramireddy, Dilip Kumar Behara
To formulate and optimize Ozenoxacin nano-emulsion using Quality by Design (QbD) concept by means of Box-Behnken Design (BBD) and converting it to a gel to form Ozenoxacin nano-emulgel followed by physico-chemical, in-vitro, ex-vivo and in-vivo evaluation. This study demonstrates the application of QbD methodology for the development and optimization of an effective topical nanoemulgel formulation for the treatment of Impetigo focusing on the selection of appropriate excipients, optimization of formulation and process variables, and characterization of critical quality attributes...
April 22, 2024: AAPS PharmSciTech
https://read.qxmd.com/read/38648848/life-years-gained-from-the-fda-accelerated-approval-program-in-oncology-a-portfolio-model
#5
JOURNAL ARTICLE
Ágnes Benedict, Gábor Szabó, Kinga Marczell, Bridget Doherty, Silas Martin
BACKGROUND: Although the FDA Accelerated Approval Program (AAP) has come under scrutiny, the population-level health benefit of the program has not been quantified. Therefore, the objective of this study was to estimate the number of life years gained among patients with cancer that can be attributable to the therapies receiving FDA accelerated approvals in oncology between 2006 and 2022 in the United States. METHODS: The data sources used were FDA listings, FDA approval letters and labels, published clinical trial data and other publications including relative effectiveness estimates, and the Ipsos Oncology Uptake Tool for product uptake...
April 22, 2024: Journal of the National Comprehensive Cancer Network: JNCCN
https://read.qxmd.com/read/38648607/author-response-pediatric-and-adult-brain-death-death-by-neurologic-criteria-consensus-guideline-report-of-the-aan-guidelines-subcommittee-aap-cns-and-sccm
#6
JOURNAL ARTICLE
Ariane Lewis, Matthew P Kirschen, David M Greer
No abstract text is available yet for this article.
May 14, 2024: Neurology
https://read.qxmd.com/read/38648606/reader-response-pediatric-and-adult-brain-death-death-by-neurologic-criteria-consensus-guideline-report-of-the-aan-guidelines-subcommittee-aap-cns-and-sccm
#7
JOURNAL ARTICLE
Christopher A DeCock, James Giordano, G Kevin Donovan, Carlo S Tornatore
No abstract text is available yet for this article.
May 14, 2024: Neurology
https://read.qxmd.com/read/38648604/author-response-pediatric-and-adult-brain-death-death-by-neurologic-criteria-consensus-guideline-report-of-the-aan-guidelines-subcommittee-aap-cns-and-sccm
#8
JOURNAL ARTICLE
David M Greer, Ariane Lewis, Matthew P Kirschen
No abstract text is available yet for this article.
May 14, 2024: Neurology
https://read.qxmd.com/read/38648603/reader-response-pediatric-and-adult-brain-death-death-by-neurologic-criteria-consensus-guideline-report-of-the-aan-guidelines-subcommittee-aap-cns-and-sccm
#9
JOURNAL ARTICLE
Shahed Toossi, Tao Shen, Douglas Dragomer, Michael Nurok
No abstract text is available yet for this article.
May 14, 2024: Neurology
https://read.qxmd.com/read/38648602/editors-note-pediatric-and-adult-brain-death-death-by-neurologic-criteria-consensus-guideline-report-of-the-aan-guidelines-subcommittee-aap-cns-and-sccm
#10
JOURNAL ARTICLE
https://read.qxmd.com/read/38648601/reader-response-pediatric-and-adult-brain-death-death-by-neurologic-criteria-consensus-guideline-report-of-the-aan-guidelines-subcommittee-aap-cns-and-sccm
#11
JOURNAL ARTICLE
Ryan Feldman, Jillian Theobald, Matthew Stanton, Andrew Stolbach, Laura Tormoehlen
No abstract text is available yet for this article.
May 14, 2024: Neurology
https://read.qxmd.com/read/38648599/author-response-pediatric-and-adult-brain-death-death-by-neurologic-criteria-consensus-guideline-report-of-the-aan-guidelines-subcommittee-aap-cns-and-sccm
#12
JOURNAL ARTICLE
David M Greer, Ariane Lewis, Matthew P Kirschen, Alexander Rae-Grant, John J Halperin
No abstract text is available yet for this article.
May 14, 2024: Neurology
https://read.qxmd.com/read/38648579/author-response-pediatric-and-adult-brain-death-death-by-neurologic-criteria-consensus-guideline-report-of-the-aan-guidelines-subcommittee-aap-cns-and-sccm
#13
JOURNAL ARTICLE
David M Greer, Ariane Lewis, Panayiotis N Varelas, Matthew P Kirschen
No abstract text is available yet for this article.
May 14, 2024: Neurology
https://read.qxmd.com/read/38643087/postoperative-pain-after-single-visit-root-canal-treatments-in-necrotic-teeth-comparing-instruments-kinematics-and-apical-instrumentation-limits-a-prospective-randomized-multicenter-clinical-trial
#14
JOURNAL ARTICLE
Ricardo Machado, Guilherme Moreira, Daniel Comparin, Arthur Pimentel Barroso, Jaqueline Nascimento, Caio Cézar Randi Ferraz, Sérgio Aparecido Ignácio, Lucas da Fonseca Roberti Garcia, Rodrigo Rodrigues Amaral, David Shadid, Ulisses Xavier da Silva Neto
OBJECTIVES: This prospective randomized multicenter clinical trial (PRMCT) investigated postoperative pain after single-visit root canal treatments in teeth affected by pulp necrosis (PN), and asymptomatic apical periodontitis (AAP) (with apical radiolucent areas) or normal periradicular tissues (without apical radiolucent areas) comparing different instruments' kinematics and apical instrumentation limits. METHODS: Before chemomechanical preparation, 240 patients/teeth were randomly distributed into four groups (n = 60) according to the instruments' kinematics (rotary or reciprocating) and apical instrumentation limits (with or without intentional foraminal enlargement [IFE])...
April 20, 2024: BMC Oral Health
https://read.qxmd.com/read/38641711/fluconazole-loaded-ibuprofen-in-situ-gel-based-oral-spray-for-oropharyngeal-candidiasis-treatment
#15
JOURNAL ARTICLE
Ei Mon Khaing, Setthapong Senarat, Kritamorn Jitrangsri, Thawatchai Phaechamud
Oral candidiasis is a fungal infection affecting the oral mucous membrane, and this research specifically addresses on a localized treatment through fluconazole-loaded ibuprofen in situ gel-based oral spray. The low solubility of ibuprofen is advantageous for forming a gel when exposed to an aqueous phase. The 1% w/w fluconazole-loaded in situ gel oral sprays were developed utilizing various concentrations of ibuprofen in N-methyl pyrrolidone. The prepared solutions underwent evaluation for viscosity, surface tension, contact angle, water tolerance, gel formation, interface interaction, drug permeation, and antimicrobial studies...
April 19, 2024: AAPS PharmSciTech
https://read.qxmd.com/read/38637446/implementation-of-a-three-way-comparability-assessment-for-a-bioanalytical-anti-drug-antibody-method
#16
JOURNAL ARTICLE
Rosanna S Kwok, Ihsan Nijem, Ann Brady, Robert Hendricks
Immunogenicity evaluation is a critical part of drug development. Regulatory guidelines from multiple health agencies provide recommendations for the development and validation of anti-drug antibody (ADA) assays to assess immunogenicity in clinical trials. These recommendations primarily describe an ADA method run in one bioanalytical laboratory supporting a biotherapeutic molecule; however, there are increasing instances that may necessitate the support of the ADA method being run in more than one laboratory...
April 18, 2024: AAPS Journal
https://read.qxmd.com/read/38637409/correction-to-predicting-human-dermal-drug-concentrations-using-pbpk-modeling-and-simulation-clobetasol-propionate-case-study
#17
William W van Osdol, Jasmina Novakovic, Maxime Le Merdy, Eleftheria Tsakalozou, Priyanka Ghosh, Jessica Spires, Viera Lukacova
No abstract text is available yet for this article.
April 18, 2024: AAPS PharmSciTech
https://read.qxmd.com/read/38637407/a-comprehensive-analysis-of-biopharmaceutical-products-listed-in-the-fda-s-purple-book
#18
REVIEW
Fuduan Chen, Hao Zhong, Ging Chan, Defang Ouyang
Although biopharmaceuticals constitute around 10% of the drug landscape, eight of the ten top-selling products were biopharmaceuticals in 2023. This study did a comprehensive analysis of the FDA's Purple Book database. Firstly, our research uncovered market trends and provided insights into biologics distributions. According to the investigation, although biotechnology has advanced and legislative shifts have made the approval process faster, there are still challenges to overcome, such as molecular instability and formulation design...
April 18, 2024: AAPS PharmSciTech
https://read.qxmd.com/read/38636291/risk-of-road-traffic-injury-in-norway-1970-2022
#19
JOURNAL ARTICLE
Rune Elvik
This paper describes changes in the risk of road traffic injury in Norway during the period from 1970 to 2022. During this period, the risk of fatal and personal injury declined by more than 70 % for most groups of road users. There are five main potential explanations of a decline in the risk of injury: (1) a reduced probability of accidents that have the potential for causing injury; (2) an improved protection against injury given that an accident has occurred; (3) improved medical care increasing the survival rate, given an injury (this would reduce the number of fatalities, but not the number of injuries); (4) a tendency for the reporting of injuries in official accident statistics to decline over time; (5) uncertain or erroneous estimates of the exposure to the risk of injury...
April 17, 2024: Accident; Analysis and Prevention
https://read.qxmd.com/read/38632178/group-by-treatment-interaction-effects-in-comparative-bioavailability-studies
#20
JOURNAL ARTICLE
Helmut Schütz, Divan A Burger, Erik Cobo, David D Dubins, Tibor Farkás, Detlew Labes, Benjamin Lang, Jordi Ocaña, Arne Ring, Anastasia Shitova, Volodymyr Stus, Michael Tomashevskiy
Comparative bioavailability studies often involve multiple groups of subjects for a variety of reasons, such as clinical capacity limitations. This raises questions about the validity of pooling data from these groups in the statistical analysis and whether a group-by-treatment interaction should be evaluated. We investigated the presence or absence of group-by-treatment interactions through both simulation techniques and a meta-study of well-controlled trials. Our findings reveal that the test falsely detects an interaction when no true group-by-treatment interaction exists...
April 17, 2024: AAPS Journal
keyword
keyword
116802
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.